Krebs Biochemicals and Industries share news, announcements and annual reports
NSE: KREBSBIOBSE: 524518Pharmaceuticals & BiotechnologySmall Cap
Krebs Biochemicals and Industries Limited · Formerly Krebs Biochemicals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on NSE, May 2000 on BSE
Last close ₹56.60down ₹1.33 (2.30%)BSE ₹58.36
Share price at the NSE close on 30 Oct 2026. Previous close ₹57.93.
30 Oct: open ₹56.60, high ₹58.49, low ₹56.33
52-week range of traded prices to 30 Oct 2026
₹38.33Low, 30 Mar 2026₹76.85High, 5 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹122 Cr2,740th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Net worth zero or below
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −14.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- Net worth zero or below
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,39760.1% delivered
Krebs Biochemicals and Industries disputes and clarifications
23 filed, newest first.
Apr 2026
10 Apr · Legal
The exchange asked on 8 Apr 2026
Dec 2024
11 Dec · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Nov 2024
27 Nov · Legal
Significant movement in price has been observed in Krebs Biochemicals and Industries Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Apr 2023
10 Apr · Legal
The exchange asked on 10 Apr 2023
Nov 2021
11 Nov · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited with respect to announcement dated 09-Nov-2021, regarding Appointment of Mr. Jitendra Shah as Additional Non-Executive Director. On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.The response of the Company is awaited.
Aug 2021
3 Aug · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited with respect to announcement dated 30-Jul-2021, regarding board meeting held on July 30, 2021. On basis of above the Company is required to clarify following: 1. Disclosure of relationships between directors (in case of appointment of a director); 2. Provide confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018. The response of the Company is awaited.
Jun 2021
23 Jun · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited with respect to announcement dated 22-Jun-2021, regarding strikes/lockouts/disturbances. On basis of above the Company is required to clarify following: 1. Estimated impact on the production/operations in case of strikes/lock outs;2. Factory/unit where the strike/lock out takes place including reasons for such strike.The response of the Company is awaited.
Apr 2021
10 Apr · Legal
The exchange asked on 9 Apr 2021
Nov 2020
Oct 2020
30 Oct · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited with respect to announcement dated 23-Oct-2020, regarding strikes/lockouts/disturbances. On basis of above the Company is required to clarify following: 1. Estimated impact on the production/operations in case of strikes/lock outs. The response of the Company is awaited.
Aug 2020
4 Aug · Legal
The exchange asked on 3 Aug 2020
Sep 2019
10 Sep · Legal
The exchange asked on 9 Sep 2019
Aug 2019
23 Aug · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited with respect to announcement dated 09-Aug-2019, regarding Intimation under Regulation 30 of SEBI (LODR) Regulations,2015. On basis of above the Company is required to clarify following: 1. Date and term of appointment of Ms. Taruni Banda. 2. Reason for resignation Ms Haritha Varanasi.The response of the Company is awaited.
Jun 2019
May 2019
27 May · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited with respect to announcement dated 20-May-2019, regarding Board meeting held on May 20, 2019. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
Sep 2018
12 Sep · Legal
Exchange has sought clarification from Krebs Biochemicals and Industries Limited with respect to announcement dated 10-Sep-2018, regarding " Krebs Biochemicals and Industries Limited has informed the Exchange regarding Board meeting held on September 10, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); 2. Date of appointment/cessation (as applicable) & term of appointment; The response of the Company is awaited.